Merck KGaA Finds R&D Nuggets: Plans Further Atacicept Studies In Lupus
This article was originally published in The Pink Sheet Daily
A discussion with internal and external experts restarts clinical development of atacicept for lupus after a two-year hiatus.
You may also be interested in...
German biotech could realize more than $2bn in earnouts under pact with Roivant. Galmed teams with MyBiotics in attempt to optimize clinical response to its Phase III NASH candidate Aramchol.
Pipeline review resulted in new focus and products with high value, exec explains.
Mid-sized German pharma says partnering will be part of its future, as it progresses three key pipeline assets and initiates talks with big pharma players wanting to partner its anti-PD-L1 compound.